Académique Documents
Professionnel Documents
Culture Documents
Projeto:
1. DADOS DO PROJETO
Processo: 150435/2015-0
Supervisor:
Prof. Dr. Jamil Assreuy
Universidade Federal de Santa Catarina - UFSC - Departamento de
Farmacologia CCB Bloco D Florianopolis-SC
e-mail: jamil.assreuy@ufsc.br
Telefone: (048) 3721-2467
Vigncia:
De 01/07/2015 a 30/06/2016
Dados da ps-doutoranda:
Nome:
Vernica Vargas Horewicz
Formao profissional:
Graduao em Odontologia (Universidade Estadual de Ponta Grossa, 2002),
Mestre em Odontologia, rea de concentrao em Periodontia (Centro de
3
3. IDENTIFICAO DA PROPOSTA
4.2 Metas
Iniciamos o projeto cumprindo as seguintes metas relacionadas ao estudo
das aes anti-inflamatrias resultantes da estimulao do receptor FPR2/ALX
no modelo de sepse induzida por pneumonia:
Avaliao de alguns efeitos anti-inflamatrios e pr-inflamatrios da
estimulao do receptor (perfil de citocinas, produo de NO e espcies
reativas de oxignio [ERO], etc) para verificao de congruncia temporal
com os efeitos cardiovasculares;
Meta parcialmente atingida (em torno de 80%). Os resultados
esto apresentados nas Figuras de 1-10.
Avaliar quais possveis vias de sinalizao intracelular ativadas pelo
receptor FPR2/ALX explicam suas aes cardiovasculares e se so as
mesmas dos seus efeitos na resposta inflamatria.
Meta parcialmente atingida (em torno de 70%). Os resultados
esto apresentados nas Figuras de 12-16.
Avaliar temporalmente a capacidade contrtil de anis de aorta e de
microvasos no modelo de sepse induzida por pneumonia em
camundongos e os efeitos decorrentes da estimulao/bloqueio do
receptor FPR2/ALX;
Meta parcialmente atingida (50%). O resultado est apresentado
na Figura 11.
9
5. RESULTADOS
foi avaliada por ate 5 dias. Os resultados foram expressos como porcentagem
de sobrevivencia. A analise estatistica utilizada foi o teste de log rank. * p < 0,05
(controle versus PS) e # p < 0,05 (PS versus PS + WKYMVm). n = 8 por grupo.
de camundongos com sepse induzida por CLP (24 h ps-sepse) (Gobbetti et al.,
2014).
6. CONCLUSES
7. REFERNCIAS BIBLIOGRFICAS
1. Angus DC, Pereira CA, Silva E. Epidemiology of severe sepsis around the
world. Endocr Metab Immune Disord Drug Targets. 2006 Jun;6(2):207-12.
2. Arlati, S. et al. Myocardial necrosis in ICU patients with acute non-cardiac
disease: a prospective study. Intensive care medicine, v. 26, n. 1, p. 317,
jan. 2000.
3. Baek SH, Seo JK, Chae CB, Suh PG, Ryu SH. Identification of the
peptides that stimulate the phosphoinositide, hydrolysis in lymphocyte cell
lines from peptide libraries. J. Biol. Chem. 1996, 271, 81708175.
4. Berkestedt I, Nelson A, Bodelsson M. Endogenous antimicrobial peptide
LL-37 induces human vasodilatation. Br. J. Anaesth. 2008; 100(6), 803-9.
5. Cattaneo, F.; Parisi, M.; Ammendola, R. Distinct signaling cascades
elicited by different formyl peptide receptor 2 (FPR2) agonists. Int. J. Mol.
Sci. 14(4): p. 7193-230. 2013.
6. Celes, M. R. N. et al. Reduction of gap and adherens junction proteins and
intercalated disc structural remodeling in the hearts of mice submitted to
severe cecal ligation and puncture sepsis. Critical care medicine, v. 35, n.
9, p. 2176- 85, 2007.
7. Da Silva-Santos, J. E., Chiao, C. W., Leite, R. E Webb, R. C. The Rho-
A/Rho-kinase pathway is up-regulated but remains inhibited by cyclic
guanosine monophosphate-dependent mechanisms during endotoxemia
in small mesenteric arteries. Crit Care Med. 2009; 37(5): 1716-1723.
8. Daniela Dal-Secco, Vania Olivon, Mara R Nunes, Silvia Dal Bo, Monica A
Azevedo, Marcos A Rossi, Ana Maria Oliveira, Fernando Q Cunha, Jamil
Assreuy. Cardiovascular hyporesponsiveness in sepsis is associated with
G-protein receptor kinase (GRK) expression via a nitric oxide-dependent
mechanism. Trabalho no publicado.
9. Dufton N, Perretti M. Therapeutic anti-inflammatory potential of formyl-
peptide receptor agonists. Pharmacology & Therapeutics, v. 127, n. 2, p.
175-88, ago. 2010.
10. Gobbetti, T. et al. Nonredundant protective properties of FPR2/ALX in
polymicrobial murine sepsis. Proc. Natl. Acad. Sci. U S A. 111(52): p.
18685-90. 2014.
11. Horewicz VV, Crestani S, Sordi R, Rezende E, Assreuy J. FPR2/ALX
activation reverses LPS-induced vascular hyporeactivity in aorta and
increases survival in a pneumosepsis model. Eur J Pharmacol. 2014 Dec
2;746C:267-273. doi: 10.1016/j.ejphar.2014.11.026
12. Kim SD, Kim YK, Lee HY, Kim YS, Jeon SG, Baek SH, Song DK, Ryu SH,
Bae YS. The agonists of formyl peptide receptors prevent development of
severe sepsis after microbial infection. J Immunol. 2010 Oct
1;185(7):4302-10.
13. Kumar, G. et al. Nationwide trends of severe sepsis in the 21st century
(2000-2007). Chest, v. 140, n. 5, p. 122331, nov. 2011.
36
14. Machado FR, Mazza BF. Improving mortality in sepsis: analysis of clinical
trials. Shock. 2010 Sep;34 Suppl 1:54-8. doi:
10.1097/SHK.0b013e3181e7e8b4.
15. Migeotte I, Communi D, Parmentier M. Formyl peptide receptors: a
promiscuous subfamily of G protein-coupled receptors controlling immune
responses. Cytokine & growth factor rev. 2006; 17(6), 501-19.
16. Muller-Werdan, U. et al. Septic cardiomyopathy A not yet discovered
cardiomyopathy? Clinical cardiology, v. 11, n. 3, p. 226-36, 2006.
17. Penn, R. B.; A. N. Pronin; J. L. Benovic. Regulation of G protein-coupled
receptor kinases. Trends Cardiovasc Med, v. 10, p. 81-9, Feb, 2000. n. 2.
18. Rockman, H. A.; D. J. Choi; S. A. Akhter; M. Jaber; B. Giros; R. J.
Lefkowitz; M. G. Caron; W. J. Koch. Control of myocardial contractile
function by the level of beta-adrenergic receptor kinase 1 in gene-targeted
mice. J Biol Chem, v. 273, p. 18180-4, Jul 17, 1998. n. 29.
19. Rossi, M. A et al. Myocardial structural changes in long-term human
severe sepsis/septic shock may be responsible for cardiac dysfunction.
Shock, v. 27, n. 1, p. 108, jan. 2007.
20. Rudiger, A.; Singer, M. Mechanisms of sepsis-induced cardiac
dysfunction. Critical care medicine, v. 35, n. 6, p. 1599608, jun. 2007.
21. Scannell M, Maderna P. Lipoxins and annexin-1: resolution of
inflammation and regulation of phagocytosis of apoptotic cells.
TheScientificWorldJournal, v. 6, p. 1555-73, jan. 2006.
22. Silva E, Pedro Mde A, Sogayar AC, Mohovic T, Silva CL, Janiszewski M,
Cal RG, de Sousa EF, Abe TP, de Andrade J, de Matos JD, Rezende E,
Assuno M, Avezum A, Rocha PC, de Matos GF, Bento AM, Corra AD,
Vieira PC, Knobel E; Brazilian Sepsis Epidemiological Study. Brazilian
Sepsis Epidemiological Study (BASES study). Crit Care. 2004
Aug;8(4):R251-60. Epub 2004 Jun 15.
23. Sordi R, Menezes-de-Lima O Jr, Horewicz V, Scheschowitsch K, Santos
LF, Assreuy J. Dual role of lipoxin A4 in pneumosepsis pathogenesis. Int.
Immunopharmacol., 2013; 17(2), 283-92.
24. von der Weid PY, Hollenberg MD, Fiorucci S, Wallace JL. Aspirin-
triggered, cyclooxygenase-2-dependent lipoxin synthesis modulates
vascular tone. Circulation. 2004; 110(10), 1320-5.
25. Wenceslau CF, McCarthy CG, Szasz T, Webb RC. Lipoxin A4 mediates
aortic contraction via RHOA/RHO kinase, endothelial dysfunction and
reactive oxygen species. J Vasc Res. 2014;51(6):407-17. doi:
10.1159/000371490.
26. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N. Eng. J.
Med., 340: 207-214, 1999.
27. Ye RD, Boulay F, Wang JM, Dahlgren C, Gerard C, Parmentier M, Serhan
CN, Murphy PM. International Union of Basic and Clinical Pharmacology.
LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.
Pharmacol. Rev., 2009; 61 (2): 119-61.
37